{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T08:54:32Z","timestamp":1772528072182,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T00:00:00Z","timestamp":1619136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T00:00:00Z","timestamp":1619136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Qatar National Library"},{"DOI":"10.13039\/100007458","name":"Qatar Foundation","doi-asserted-by":"publisher","award":["4-157-3\u2013052"],"award-info":[{"award-number":["4-157-3\u2013052"]}],"id":[{"id":"10.13039\/100007458","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007833","name":"Hamad Medical Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007833","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Protein tyrosine phosphatase receptor gamma (<jats:italic>PTPRG<\/jats:italic>) is a member of the receptor-like family protein tyrosine phosphatases and acts as a tumor suppressor gene in different neoplasms. Recent studies reported the down-regulation of <jats:italic>PTPRG<\/jats:italic> expression levels in Chronic Myeloid Leukemia disease (CML). In addition, the <jats:italic>BCR-ABL1<\/jats:italic> transcript level is currently a key predictive biomarker of CML response to treatment with Tyrosine Kinase Inhibitors (TKIs). The aim of this study was to employ flow cytometry to monitor the changes in the expression level of PTPRG in the white blood cells (WBCs) of CML patients at the time of diagnosis and following treatment with TKIs. WBCs from peripheral blood of 21 CML patients were extracted at diagnosis and during follow up along with seven healthy individuals. The PTPRG expression level was determined at protein and mRNA levels by both flow cytometry with monoclonal antibody (TP\u03b3 B9-2) and RT-qPCR, and <jats:italic>BCR-ABL1<\/jats:italic> transcript by RT-qPCR, respectively. PTPRG expression was found to be lower in the neutrophils and monocytes of CML patients at time of diagnosis compared to healthy individuals. Treatment with TKIs nilotinib and Imatinib Mesylate restored the expression of PTPRG in the WBCs of CML patients to levels observed in healthy controls. Moreover, restoration levels were greatest in optimal responders and occurred earlier with nilotinib compared to imatinib. Our results support the measurement of PTPRG expression level in the WBCs of CML patients by flow cytometry as a monitoring tool for the response to treatment with TKIs in CML patients.<\/jats:p>","DOI":"10.1038\/s41598-021-86875-y","type":"journal-article","created":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T10:12:30Z","timestamp":1619172750000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients"],"prefix":"10.1038","volume":"11","author":[{"given":"Mohamed A.","family":"Ismail","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marzia","family":"Vezzalini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisham","family":"Morsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Abujaber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Al Sayab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kodappully","family":"Siveen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed A.","family":"Yassin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Monne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muthanna","family":"Samara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Cook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Sorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmout","family":"Modjtahedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nader I.","family":"Al-Dewik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,23]]},"reference":[{"issue":"5","key":"86875_CR1","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1634\/theoncologist.2015-0337","volume":"21","author":"S Soverini","year":"2016","unstructured":"Soverini, S. et al. Best practices in chronic myeloid leukemia monitoring and management. Oncologist 21(5), 626\u2013633 (2016).","journal-title":"Oncologist"},{"key":"86875_CR2","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3389\/fonc.2019.00603","volume":"9","author":"V Garcia-Gutierrez","year":"2019","unstructured":"Garcia-Gutierrez, V. & Hernandez-Boluda, J. C. Tyrosine kinase inhibitors available for chronic myeloid leukemia: Efficacy and safety. Front. Oncol. 9, 603 (2019).","journal-title":"Front. Oncol."},{"issue":"1","key":"86875_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/10428194.2018.1466294","volume":"60","author":"A Gover-Proaktor","year":"2019","unstructured":"Gover-Proaktor, A. et al. Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells. Leuk. Lymphoma 60(1), 189\u2013199 (2019).","journal-title":"Leuk. Lymphoma"},{"issue":"4","key":"86875_CR4","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.hoc.2017.04.007","volume":"31","author":"AB Patel","year":"2017","unstructured":"Patel, A. B., O\u2019Hare, T. & Deininger, M. W. Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors. Hematol. Oncol. Clin. N. Am. 31(4), 589\u2013612 (2017).","journal-title":"Hematol. Oncol. Clin. N. Am."},{"issue":"3","key":"86875_CR5","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1128\/MCB.13.3.1497","volume":"13","author":"G Barnea","year":"1993","unstructured":"Barnea, G. et al. Identification of a carbonic anhydrase-like domain in the extracellular region of RPTP gamma defines a new subfamily of receptor tyrosine phosphatases. Mol. Cell Biol. 13(3), 1497\u20131506 (1993).","journal-title":"Mol. Cell Biol."},{"issue":"11","key":"86875_CR6","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/nrm2039","volume":"7","author":"NK Tonks","year":"2006","unstructured":"Tonks, N. K. Protein tyrosine phosphatases: From genes, to function, to disease. Nat. Rev. Mol. Cell Biol. 7(11), 833\u2013846 (2006).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"2","key":"86875_CR7","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1006\/geno.1996.0109","volume":"32","author":"K Kastury","year":"1996","unstructured":"Kastury, K. et al. Structure of the human receptor tyrosine phosphatase gamma gene (PTPRG) and relation to the familial RCC t(3;8) chromosome translocation. Genomics 32(2), 225\u2013235 (1996).","journal-title":"Genomics"},{"key":"86875_CR8","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1177\/117727190700200036","volume":"2","author":"A Mafficini","year":"2007","unstructured":"Mafficini, A. et al. Protein tyrosine phosphatase gamma (PTPgamma) is a novel leukocyte marker highly expressed by CD34 precursors. Biomark. Insights 2, 218\u2013225 (2007).","journal-title":"Biomark. Insights"},{"issue":"21","key":"86875_CR9","doi-asserted-by":"publisher","first-page":"8896","DOI":"10.1158\/0008-5472.CAN-10-0258","volume":"70","author":"M Della Peruta","year":"2010","unstructured":"Della Peruta, M. et al. Protein tyrosine phosphatase receptor type gamma is a functional tumor suppressor gene specifically downregulated in chronic myeloid leukemia. Cancer Res. 70(21), 8896\u20138906 (2010).","journal-title":"Cancer Res."},{"issue":"10","key":"86875_CR10","doi-asserted-by":"publisher","first-page":"9442","DOI":"10.18632\/oncotarget.24253","volume":"9","author":"J Drube","year":"2018","unstructured":"Drube, J. et al. PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cells. Oncotarget 9(10), 9442\u20139455 (2018).","journal-title":"Oncotarget"},{"issue":"22","key":"86875_CR11","doi-asserted-by":"publisher","first-page":"5427","DOI":"10.1182\/blood.V128.22.5427.5427","volume":"128","author":"NI Al-Dewik","year":"2016","unstructured":"Al-Dewik, N. I. et al. Novel molecular findings in protein tyrosine phosphatase receptor gamma (PTPRG) among chronic myelocytic leukemia (CML) patients studied by next generation sequencing (NGS): A pilot study in patients from the State of Qatar and Italy. Blood 128(22), 5427 (2016).","journal-title":"Blood"},{"key":"86875_CR12","doi-asserted-by":"publisher","unstructured":"Ismail, M. A. et al. Aberrant DNA methylation of PTPRG as one possible mechanism of its under-expression in CML patients in the State of Qatar. Mol. Genet. Genom. Med. 8, e1319. https:\/\/doi.org\/10.1002\/mgg3.1319 (2020).","DOI":"10.1002\/mgg3.1319"},{"key":"86875_CR13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3109\/00365519509090577","volume":"221","author":"A Orfao","year":"1995","unstructured":"Orfao, A. et al. Flow cytometry in the diagnosis of cancer. Scand. J. Clin. Lab. Invest. Suppl. 221, 145\u2013152 (1995).","journal-title":"Scand. J. Clin. Lab. Invest. Suppl."},{"issue":"10","key":"86875_CR14","doi-asserted-by":"publisher","first-page":"e617","DOI":"10.1038\/bcj.2017.90","volume":"7","author":"T Jelinek","year":"2017","unstructured":"Jelinek, T. et al. Current applications of multiparameter flow cytometry in plasma cell disorders. Blood Cancer J. 7(10), e617 (2017).","journal-title":"Blood Cancer J."},{"key":"86875_CR15","unstructured":"Ormerod, M.G. (ed) Chapter 7: Some Clinical Applications|Flow Cytometry\u2014A Basic Introduction. (2008)."},{"issue":"7","key":"86875_CR16","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3324\/haematol.2011.043166","volume":"96","author":"CM Lucas","year":"2011","unstructured":"Lucas, C. M. et al. Rapid diagnosis of chronic myeloid leukemia by flow cytometric detection of BCR-ABL1 protein. Haematologica 96(7), 1077 (2011).","journal-title":"Haematologica"},{"issue":"1","key":"86875_CR17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13045-017-0494-z","volume":"10","author":"M Vezzalini","year":"2017","unstructured":"Vezzalini, M. et al. A new monoclonal antibody detects downregulation of protein tyrosine phosphatase receptor type gamma in chronic myeloid leukemia patients. J. Hematol. Oncol. 10(1), 129 (2017).","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"86875_CR18","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/embor.2011.262","volume":"13","author":"H Zur","year":"2012","unstructured":"Zur, H. & Tuller, T. Strong association between mRNA folding strength and protein abundance in S. cerevisiae. EMBO Rep. 13(3), 272 (2012).","journal-title":"EMBO Rep."},{"key":"86875_CR19","doi-asserted-by":"crossref","unstructured":"Vogel, C. & Marcotte, E.M. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat. Rev. Genet. 13(4) (2012).","DOI":"10.1038\/nrg3185"},{"key":"86875_CR20","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/msb.2011.81","volume":"7","author":"N Nagaraj","year":"2011","unstructured":"Nagaraj, N. et al. Deep proteome and transcriptome mapping of a human cancer cell line. Mol. Syst. Biol. 7, 548 (2011).","journal-title":"Mol. Syst. Biol."},{"issue":"1","key":"86875_CR21","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s12864-017-3683-9","volume":"18","author":"K Perl","year":"2017","unstructured":"Perl, K. et al. Reduced changes in protein compared to mRNA levels across non-proliferating tissues. BMC Genom. 18(1), 305 (2017).","journal-title":"BMC Genom."},{"issue":"1\u20132","key":"86875_CR22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1159\/000444534","volume":"98","author":"MS Karbownik","year":"2016","unstructured":"Karbownik, M. S. et al. Antipsychotic drugs differentially affect mRNA expression of genes encoding the neuregulin 1-downstream ErbB4-PI3K pathway. Pharmacology 98(1\u20132), 4\u201312 (2016).","journal-title":"Pharmacology"},{"issue":"19","key":"86875_CR23","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1002\/pmic.201600140","volume":"16","author":"D Kumar","year":"2016","unstructured":"Kumar, D. et al. Integrating transcriptome and proteome profiling: Strategies and applications. Proteomics 16(19), 2533\u20132544 (2016).","journal-title":"Proteomics"},{"key":"86875_CR24","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/S0378-6080(08)00045-7","volume":"30","author":"H-P Lipp","year":"2008","unstructured":"Lipp, H.-P. & Hartmann, J. T. 45\u2014Cytostatic and cytotoxic drugs. Side Effects Drugs Annu. 30, 520\u2013532 (2008).","journal-title":"Side Effects Drugs Annu."},{"issue":"3","key":"86875_CR25","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1532\/IJH97.04095","volume":"81","author":"N Takahashi","year":"2005","unstructured":"Takahashi, N. et al. Fluorescence in situ hybridization monitoring of BCR-ABL-positive neutrophils in chronic-phase chronic myeloid leukemia patients during the primary stage of imatinib mesylate therapy. Int. J. Hematol. 81(3), 235\u2013241 (2005).","journal-title":"Int. J. Hematol."},{"issue":"16","key":"86875_CR26","doi-asserted-by":"publisher","first-page":"4030","DOI":"10.1158\/1078-0432.CCR-15-2791","volume":"22","author":"N Thielen","year":"2016","unstructured":"Thielen, N. et al. Leukemic stem cell quantification in newly diagnosed patients with chronic myeloid leukemia predicts response to nilotinib therapy. Clin. Cancer Res. 22(16), 4030\u20134038 (2016).","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"86875_CR27","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s12185-011-0901-0","volume":"94","author":"FH Heidel","year":"2011","unstructured":"Heidel, F. H., Mar, B. G. & Armstrong, S. A. Self-renewal related signaling in myeloid leukemia stem cells. Int. J. Hematol. 94(2), 109 (2011).","journal-title":"Int. J. Hematol."},{"issue":"24","key":"86875_CR28","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1001\/jama.2010.1862","volume":"304","author":"AJ Gentles","year":"2010","unstructured":"Gentles, A. J. et al. A leukemic stem cell gene expression signature is associated with clinical outcomes in acute myeloid leukemia. JAMA J. Am. Med. Assoc. 304(24), 2706 (2010).","journal-title":"JAMA J. Am. Med. Assoc."},{"issue":"21","key":"86875_CR29","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1182\/blood.V116.21.952.952","volume":"116","author":"CM Woolthuis","year":"2010","unstructured":"Woolthuis, C. M. et al. Gene expression profiling in leukemic stem cell-enriched AML CD34+ cell fraction identifies target genes that predict prognosis In normal karyotype AML. Blood 116(21), 952 (2010).","journal-title":"Blood"},{"issue":"7","key":"86875_CR30","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1038\/s41375-019-0490-0","volume":"33","author":"M Houshmand","year":"2019","unstructured":"Houshmand, M. et al. Chronic myeloid leukemia stem cells. Leukemia 33(7), 1543\u20131556 (2019).","journal-title":"Leukemia"},{"issue":"11","key":"86875_CR31","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","volume":"8","author":"JF Apperley","year":"2007","unstructured":"Apperley, J. F. Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 8(11), 1018\u20131029 (2007).","journal-title":"Lancet Oncol."},{"key":"86875_CR32","first-page":"63","volume":"7","author":"NI Al-Dewik","year":"2015","unstructured":"Al-Dewik, N. I. et al. Studying the impact of presence of alpha acid glycoprotein and protein glycoprotein in chronic myeloid leukemia patients treated with imatinib mesylate in the State of Qatar. Biomark. Cancer 7, 63\u201367 (2015).","journal-title":"Biomark. Cancer"},{"issue":"10","key":"86875_CR33","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1038\/s41375-019-0562-1","volume":"33","author":"M Baccarani","year":"2019","unstructured":"Baccarani, M., Rosti, G. & Soverini, S. Chronic myeloid leukemia: The concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type. Leukemia 33(10), 2358\u20132364 (2019).","journal-title":"Leukemia"},{"issue":"24","key":"86875_CR34","doi-asserted-by":"publisher","first-page":"7519","DOI":"10.1158\/1078-0432.CCR-09-1068","volume":"15","author":"D Milojkovic","year":"2009","unstructured":"Milojkovic, D. & Apperley, J. Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia. Clin. Cancer Res. 15(24), 7519\u20137527 (2009).","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"86875_CR35","doi-asserted-by":"publisher","first-page":"24","DOI":"10.5339\/connect.2014.24","volume":"2014","author":"NI Al-Dewik","year":"2014","unstructured":"Al-Dewik, N. I. et al. Molecular monitoring of patients with chronic myeloid leukemia (CML) in the State of Qatar: Optimization of techniques and response to imatinib. QScience Connect 2014(1), 24 (2014).","journal-title":"QScience Connect"},{"issue":"6","key":"86875_CR36","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani, M. et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6), 872\u2013884 (2013).","journal-title":"Blood"},{"key":"86875_CR37","doi-asserted-by":"publisher","first-page":"95","DOI":"10.4137\/CMO.S32822","volume":"10","author":"NI Al-Dewik","year":"2016","unstructured":"Al-Dewik, N. I. et al. Is Adherence to imatinib mesylate treatment among patients with chronic myeloid leukemia associated with better clinical outcomes in Qatar?. Clin. Med. Insights. Oncol. 10, 95 (2016).","journal-title":"Clin. Med. Insights. Oncol."},{"issue":"1","key":"86875_CR38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.5339\/connect.2014.13","volume":"2014","author":"NI Al-Dewik","year":"2014","unstructured":"Al-Dewik, N. I. et al. Studying the impact of presence of point mutation, insertion mutation and additional chromosomal abnormalities in chronic myeloid leukemia patients treated with imatinib mesylate in the State of Qatar. QScience Connect 2014(1), 13 (2014).","journal-title":"QScience Connect"},{"key":"86875_CR39","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"C Jacon","year":"1998","unstructured":"Jacon, C. Statistical Power Analysis for the Behavioral Sciences (Routledge Academic-New York, 1998)."},{"issue":"2","key":"86875_CR40","doi-asserted-by":"publisher","first-page":"597","DOI":"10.22237\/jmasm\/1257035100","volume":"82","author":"SS Sawilowsky","year":"2009","unstructured":"Sawilowsky, S.S. New effect size rules of thumb. J. Mod. Appl. Stat. Meth. 82(2), 597\u2013599 (2009).","journal-title":"J. Mod. Appl. Stat. Meth."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86875-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86875-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86875-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T07:05:35Z","timestamp":1670051135000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86875-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,23]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["86875"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-86875-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,23]]},"assertion":[{"value":"20 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8833"}}